Johnson & Johnson
Analysis Terminal
Aggregated from brotherhood trade streams
"Johnson & Johnson announced an executive leadership change, with Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, retiring and Tom Cavanaugh appointed as her successor. Taubert oversaw the growth of the Innovative Medicine business to over $60 billion in annual revenue. JNJ was also identified as a non-tech stock with strong earnings growth, performing well as the Dow reached a new milestone amidst an AI-driven tech sell-off."
Asset Intelligence
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
NEW BRUNSWICK, N.J., August 04, 2026--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical businesses in
4 Non-Tech Stocks to Grab as Dow Hits New Milestone Amid AI Sell-off
GS, JPM, TRV and JNJ stand out as Dow hits a new high amid an AI-driven tech sell-off, with these blue-chip stocks backed by strong earnings growth.
Medicare Now Takes $202.90 a Month Straight From Your Social Security Check. These 3 ETFs Pay It Back
Medicare quietly pockets a chunk of your Social Security before it ever reaches you, and the gap between what you expect and what you receive keeps widening every year. Three ETFs target that exact shortfall with income built to arrive on a schedule.
$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off
The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.
AbbVie's Growth Now Leans On A Single Molecule
SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.
Stock Market Today: Dow Rises To Record As Amazon Jumps; This Cathie Wood Trade Nets $2.9 Mil (Live Coverage)
Stock Market Today: The Dow Jones index pops as oil stocks lag amid Trump Iran moves. Amazon clears a milestone. A Cathie Wood trade pays off.
Explore the top gainers and losers within the dow jones index in today's session.
Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
Johnson & Johnson (JNJ) Gets FDA Nod For OTTAVA As It Enters Surgical Robotics
Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of OTTAVA as its first table integrated, soft tissue robotic platform. This marks Johnson & Johnson's entry into the competitive surgical robotics market with a differentiated system design. For investors watching Johnson & Johnson, the OTTAVA approval adds a new dimension to the MedTech story. Surgical robotics has become a focus area for...
Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?
Stock Market Today: Dow Jumps 600 Points On Trump Strikes Reversal; Oil Prices Plunge (Live Coverage)
Stock Market Today: The Dow Jones index rallies 600 points Monday as Trump calls off new U.S. strikes on Iran. Oil prices plunge.
Top dow jones movers in Monday's session
Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Monday.
Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone
Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode. After days of urging investors to accumulate the stock following a strong earnings report that Wall Street initially dismissed, Cramer highlighted the FDA approval of JNJ’s OTTAVA Robotic Surgical System as the catalyst that finally […]
Stocks mixed as AstraZeneca merger talk dents FTSE 100
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes
J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Integrity Notice
TWB Intelligence is provided for mastery education only. Market data is sourced via institutional nodes and may contain inaccuracies. Trade with discipline.